ArticleCancer cell2025
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients.
Registry-linked trialAbstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07325539 (Low-dose Radiotherapy), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low-dose Radiotherapy (LDRT) Combined With Toripalimab and GP Chemotherapy for Recurrent/Metastatic Nasopharyngeal Carcinoma (LIGHT): A Multicentre, Open-Label, Single-Arm Phase II Clinical Study
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta-Analysis.International journal of cancer · 2026Pooled it
- Preliminary results from a phase II trial of spatially fractionated radiotherapy combined with immunotherapy and anti-angiogenic therapy in patients with bulky solid tumors: early evidence of promising efficacy and favorable safety.Radiation oncology (London, England) · 2026Trial
- Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.Nature communications · 2025Trial
- Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research.Oncoimmunology · 2026Review
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Review
- Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy.The Journal of clinical investigation · 2026Review
- Low-Dose Intestinal Irradiation Enhances the Efficacy and Prognosis of PD-1 Blockade in Metastatic Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- RAS signaling at the crossroads of radioresistance and tumor immunity.Journal for immunotherapy of cancer · 2026Review
- A Microbial Lipid-ATP Synthase Axis Fuels NK Cell Antitumor Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Radiotherapy synergizes with CD24 blockade to initiate macrophage-driven systemic antitumor immunity in non-small cell lung cancer.Experimental hematology & oncology · 2026Article
- The microbiome across the prostate disease continuum: from health and BPH to prostatitis/CPPS and cancer.Oncogene · 2026Review
- DNA-PK-mediated CRTC2 phosphorylation promotes NHEJ and suppresses antitumor immunity via relocation to repair complexes.Nature communications · 2026Article
- Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming.Signal transduction and targeted therapy · 2026Article
- Radiotherapy in patients with NSCLC developing progressive disease during immune checkpoint inhibition: Abscopal responses and survival.Clinical and translational radiation oncology · 2026Article
- Three-Discipline Collaborative Radiation Therapy (3DCRT) debate: Medical physics should focus less on geometric precision and more on biological outcomes.Journal of applied clinical medical physics · 2026Article
- Gut-targeted strategies at the intersection of radiotherapy and immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy.Nature reviews. Cancer · 2026Review
- Shaping death: how the microbiome regulates tumour cell demise and therapy response.Cancer metastasis reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
61 authors.
Jianzhou ChenGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China.
Antonin LevyFaculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Department of Radiation Oncology, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Ai-Ling TianGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France.
Xuehan HuangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China.
Guoxin CaiGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France.
Marine FidelleGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France; CICBT1428, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Conrad RauberGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France; Department of Gastroenterology and Infectious Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Pierre LyGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France.
Eugénie PizzatoGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France.
Lisa SitterleINSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Gianmarco PiccinnoDepartment of Computational, Cellular and Integrative Biology, University of Trento, 38123 Trento, Italy.
Peng LiuMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Cancer Campus, 94805 Villejuif, France; Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, 75006 Paris, France.
Sylvère DurandMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
Misha MaoMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Cancer Campus, 94805 Villejuif, France; Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, 75006 Paris, France; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China; Zhejiang University, Hangzhou, Zhejiang 310000, China.
Liwei ZhaoMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Cancer Campus, 94805 Villejuif, France; Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, 75006 Paris, France.
Valerio IebbaGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France.
Hannah FelchleMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Cancer Campus, 94805 Villejuif, France; Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Technical University of Munich (TUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Radiation Oncology, 81675 Munich, Germany.
Anne-Laure Mallard de La VarendeGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France.
Julius Clemens FischerMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Cancer Campus, 94805 Villejuif, France; Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Technical University of Munich (TUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Radiation Oncology, 81675 Munich, Germany.
Simon ThomasGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France.
Tim F GretenGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jennifer C JonesTranslational Nanobiology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cecilia MongeGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Sandra DemariaDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
Silvia FormentiDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
Lorenzo BelluominiSection of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, 37134 Verona, Italy.
Valeria DionisiDepartment of Radiation Oncology, University of Verona Hospital Trust, 37126 Verona, Italy.
Christophe MassardFaculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, 94805 Villejuif, France.
Pierre BlanchardFaculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Charlotte RobertINSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Clément QuevrinINSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Eloise LopesINSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Céline ClémensonINSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Michele MondiniINSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Lydia MezianiINSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Yizhou ZhanDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China.
Chengbing ZengDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China.
Qingxin CaiDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China.
Daphne MorelDepartment of Radiation Oncology, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Roger SunFaculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Department of Radiation Oncology, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Pierre-Antoine LaurentFaculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Department of Radiation Oncology, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Monica MangoniRadiotherapy Unit, Department of Experimental and Clinical Biomedical Sciences"Mario Serio" University of Florence, 50134 Florence, Italy.
Vanessa Di CataldoRadiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, 50134 Florence, Italy.
Chiara ArilliMedical Physics Unit, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy.
Maike TrommerDepartment of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany; Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, Department of Radiation Oncology, Heidelberg VIC 3084, Melbourne, Australia.
Simone WegenDepartment of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Sebastian NepplDepartment of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany.
Rachel P RiechelmannDepartment of Clinical Oncology, AC Camargo Cancer Center, São Paulo 01509-900, Brazil.
Marcos P CamandarobaDepartment of Clinical Oncology, AC Camargo Cancer Center, São Paulo 01509-900, Brazil.
Elson Santos NetoDepartment of Radiation Oncology, AC Camargo Cancer Center, São Paulo 01509-001, Brazil.
Pierre-Edouard FournierIHU Méditerranée Infection, 13005 Marseille, France.
Nicola SegataDepartment of Computational, Cellular and Integrative Biology, University of Trento, 38123 Trento, Italy; IEO, Istituto Europeo di Oncologia IRCCS, 20139 Milan, Italy.
Peter HolicekDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA; Sotio Biotech, 19000 Prague, Czech Republic.
Lorenzo GalluzziCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA.
Aitziber BuquéDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
Carolina Alves Costa SilvaGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France.
Lisa DerosaGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France; CICBT1428, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Guido KroemerMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Cancer Campus, 94805 Villejuif, France; Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France.
Chuangzhen ChenDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China. Electronic address: czchen2@stu.edu.cn.
Laurence ZitvogelGustave Roussy Cancer Campus (GRCC), Clinicobiome, 94805 Villejuif Cedex, France; Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, Equipe Labellisée-Ligue Nationale contre le Cancer, 94805 Villejuif, France; CICBT1428, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France. Electronic address: Laurence.zitvogel@gustaveroussy.fr.
Eric DeutschFaculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Department of Radiation Oncology, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
Funding
Radiation Effect on Immune Cells and the MicrobiomeU54CA274291 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI John Ng · 2022 to 2026
$9.1MNovel Combinations of Radiation and ImmunotherapyZIABC011503 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JONES, JENNIFER · 2013 to 2025
$5.3MClinical protocols for the treatment of GI cancerZIABC011343 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRETEN, TIM · 2010 to 2025
$4.8MTargeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancerR01CA271915 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Lorenzo Galluzzi · 2023 to 2026
$2.9MIntramural NIH HHS ZIA BC011343Intramural NIH HHS ZIA BC011503NCI NIH HHS R01 CA271915NCI NIH HHS U54 CA274291
Abstract
The mechanisms governing the abscopal effects of local radiotherapy in cancer patients remain an open conundrum. Here, we show that off-target intestinal low-dose irradiation (ILDR) increases the clinical benefits of immune checkpoint inhibitors or chemotherapy in eight retrospective cohorts of cancer patients and in tumor-bearing mice. The abscopal effects of ILDR depend on dosimetry (≥1 and ≤3 Gy) and on the metabolic and immune host-microbiota interaction at baseline allowing CD8
Indexed as
B7-H1 AntigenImmune Checkpoint InhibitorsIntestinesNeoplasmsAnimalsCD8-Positive T-LymphocytesFemaleGastrointestinal MicrobiomeHumansImmunotherapyMaleMiceMice, Inbred C57BLRetrospective StudiesB7-H1 AntigenCD274 protein, humanImmune Checkpoint Inhibitorsbile acidscancerChristensenella minutadendritic cellsgut microbiotametabolomicsradiotherapytumor immunosurveillance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07325539ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.